NeuralCIM Treatment
A breakthrough in neurodegenerative disease treatment offering hope to families affected by Alzheimer's and Parkinson's disease.
What is NeuralCIM?
NeuralCIM® (also known as NeuroEPO) is a variant of EPO (erythropoietin) that contains low sialic acid. Unlike traditional EPO, NeuralCIM® is devoid of hematopoietic effects — meaning it does not affect blood cell production.
Instead, NeuralCIM® produces clinical benefits in subjects with mild-to-moderate Alzheimer's clinical syndrome. This innovative treatment represents a significant advancement in addressing neurodegenerative diseases that have traditionally had limited treatment options.
Regulatory Approved
CECMED (Cuban Regulatory Authority)
Accelerated Approval
Mild-Moderate Alzheimer's Treatment
Conditions NeuralCIM Treats
Originally developed by Dr. Teresita Rodríguez Obaya, NeuralCIM has shown promising results across multiple neurodegenerative conditions.
Alzheimer's Disease
Recent research has demonstrated that NeuralCIM significantly delays, and sometimes halts, Alzheimer's disease progression — offering new hope to families affected by this devastating condition.
View Clinical DataParkinson's Disease
NeuralCIM was originally developed to treat Parkinson's disease, with clinical studies showing improvements in motor function and quality of life for patients with this progressive condition.
Learn MoreStrokes & Ataxia
The treatment has also shown benefits for stroke recovery and ataxia conditions, demonstrating the broad neuroprotective potential of this innovative medication.
Check Eligibility
How NeuralCIM Works
NeuralCIM works through its unique molecular structure — a variant of erythropoietin with low sialic acid content that provides neuroprotective benefits without affecting blood cell production.
Neuroprotection
Protects neurons from degeneration and oxidative stress
Cognitive Support
Supports cognitive function and neural communication
Disease Stabilization
Clinical studies show stabilization of disease progression with continued treatment
Proven Results
Clinical trials have demonstrated statistically significant improvements in cognitive function for patients receiving NeuralCIM treatment.
174
Study Participants
8.0
Point Improvement vs Placebo
2 Years
Disease Stabilization
Excellent Safety Profile
Patient safety is our highest priority. Clinical studies have demonstrated that NeuralCIM has a very good safety profile with comprehensive monitoring throughout the treatment period.
- No serious adverse events related to NeuralCIM reported
- Standardized cognitive assessments throughout treatment
- Continuous medical monitoring by specialized team
- 85% of participants completed the full trial
Study Completion Rate
Based on Phase 3 clinical trial results with 174 participants
Developed by Dr. Teresita Rodríguez Obaya
NeuralCIM was developed by Dr. Teresita Rodríguez Obaya, a biotechnology scientist and founder of Cuba's Centre of Molecular Immunology (CIM).
Despite the extraordinary challenges posed by the U.S. blockade — which has made it difficult to obtain research supplies and materials — Dr. Obaya and her team persevered. Their dedication has brought hope to families worldwide affected by neurodegenerative diseases.
Meet Dr. ObayaReady to Learn More?
Take the first step toward accessing this groundbreaking treatment. Our team is here to guide you through every step of the process.